Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Chung-Ang University Researchers Show A Gold-Paved Path Towards Faster COVID-19 Diagnosis

Researchers use gold nanoparticles to develop a new molecular diagnostic platform that considerably reduces the time required for COVID-19 detection

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

The rapid spread of COVID-19, a disease caused by the SARS-CoV-2 virus, has created a public health crisis around the world. Early COVID-19 detection and isolation are key for controlling disease transmission and protecting vulnerable populations.

The current standard for COVID-19 diagnosis is reverse transcriptase-polymerase chain reaction (RT-PCR), a technique in which viral genes are detected after they undergo multiples cycles of amplification. However, this technique is time-consuming, creating a testing backlog across diagnostic centers and leading to delayed diagnoses.

In a recent study published in Biosensors and Bioelectronics, researchers from Korea and China have introduced a novel nanotechnology-based platform that can shorten the time required for COVID-19 diagnosis. Their surface-enhanced Raman scattering (SERS)-PCR detection platform—prepared using gold nanoparticles (AuNPs) in the cavities of Au ‘nanodimple’ substrates (AuNDSs)—can detect viral genes after only 8 cycles of amplification. That is almost one-third of the number required with conventional RT-PCR.

Conventional RT-PCR is based on the detection of fluorescence signals, so 3–4 hours are required to detect SARS-CoV-2. This speed is not enough considering how rapidly COVID-19 spreads. We wanted to find a way to cut this time at least by half,” says Prof. Jaebum Choo, explaining the motivation behind the study. Fortunately, the answer was not too far. In a previous study published in 2021, Prof. Choo’s team had developed a novel detection platform in which high-sensitivity SERS signals are produced by AuNPs uniformly arranged in the cavities of AuNDSs through a technique called DNA hybridization. Based on this previous discovery, Prof. Choo and his team developed the novel SERS-PCR platform for COVID-19 diagnosis.

The newly developed SERS-PCR assay uses SERS signals to detect “bridge DNA”—small DNA probes that slowly break down in the presence of target viral genes. Therefore, in samples from patients positive for COVID-19, the concentration of bridge DNA (and therefore the SERS signal) continuously decreases with progressive PCR cycles. In contrast, when SARS-CoV-2 is absent, the SERS signal remains unchanged.

The team tested the effectiveness of their system using two representative target markers of SARS-CoV-2, namely, the envelope protein (E) and RNA-dependent RNA polymerase (RdRp) genes of SARS-CoV-2. While 25 cycles were required for RT-PCR-based detection, the AuNDS-based SERS-PCR platform required only 8 cycles, considerably reducing the testing duration. “Although our results are preliminary, they provide an important proof-of-concept for the validity of SERS-PCR as a diagnostic technique. Our AuNDS-based SERS-PCR technique is a promising new molecular diagnostic platform that can considerably shorten the time required for gene detection compared to conventional RT-PCR techniques. This model can be further expanded by incorporating an automatic sampler to develop a next-generation molecular diagnostic system,” explains Prof. Choo.

Indeed, SERS-PCR could be an important tool in our arsenal against the COVID-19 pandemic. It could also create a paradigm shift in the field of molecular diagnostics, revolutionizing how we detect infectious diseases and tackle future epidemics.


Title of original paper: SERS-PCR assays of SARS-CoV-2 target genes using Au nanoparticles-internalized Au nanodimple substrates
Journal: Biosensors and Bioelectronics
DOI: https://doi.org/10.1016/j.bios.2021.113736

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine